Estrella Immunopharma, Inc. (ESLA) vs PAVmed Inc. (PAVM)
A side-by-side comparison of Estrella Immunopharma, Inc. and PAVmed Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.47HealthcareDelayed quote: Oct 6, 2026, 11:51 AM EDT
PAVM
PAVmed Inc.
$2.72HealthcareDelayed quote: Oct 6, 2026, 11:52 AM EDT
Total return — ESLA vs PAVM
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)PAVM -99.9% (-76.4%/yr)ESLA compounded faster over this window
Log scale — wide-divergence pair
ESLA PAVM
ESLA vs PAVM: by the numbers
- •ESLA is the larger company ($20M vs $17M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -10794.64% net margin).
Metrics side by side
Valuation
| Metric | ESLA | PAVM |
|---|---|---|
| P/S ratio | N/A | 155.02 |
| P/B ratio | N/A | 0.56 |
Profitability
| Metric | ESLA | PAVM |
|---|---|---|
| Gross margin | 0.00% | -354.93% |
| Operating margin | 0.00% | -30712.68% |
| Net margin | 0.00% | -10794.64% |
| ROE | N/A | -34.50% |
| ROIC | N/A | -73.92% |
Growth (annualized)
| Metric | ESLA | PAVM |
|---|---|---|
| Total return CAGR (5Y) | -46.34% | -76.55% |
Frequently asked
- How have ESLA and PAVM total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and PAVM delivered -76.55% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.